Neptun-Anteile 18 $ in 1 Jahr - 500 Beiträge pro Seite

[EUinside]

Thursday, June 21, 2007
Catalyst Predicts Neptune Shares at $18 in 1 Year
http://howardgroupinsightnewsletter.blogspot.com/search/labe…

[MONSIEURCB]

Hi - bin ab heute mit im Boot...verrückt, dass dieser Wert hierzulande noch unentdeckt ist!

[MONSIEURCB]

Super-News!

Press Release Source: NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Neptune Announces Research Collaboration with Nestlé
Thursday July 12, 9:00 am ET

LAVAL, QC, July 12 /CNW/ - Neptune Technologies & Bioressources Inc. (Neptune) (NTB - TSX) is pleased to announce a collaboration with the Nestlé Research Center.

According to the signed agreement terms, Neptune and Nestlé will jointly research the effects of Neptune Krill Oil (NKO(TM)) on exceptionally prevalent conditions affecting the worldwide adult population. The research was initiated at the beginning of July 2007. The design and identification of primary investigators for the study has been completed. Upon successful completion of the trial the companies will proceed with the Development and License Agreement.

"I am extremely pleased for this cooperation between Neptune and Nestlé. With this collaboration, we are not only fulfilling a pivotal milestone we also have an opportunity to strengthen our presence in the functional food market in partnership with the world's largest food company in the rapidly growing and profitable healthcare nutrition segment," said Mr. Henri Harland, president and CEO at Neptune.

"I am very excited about the opportunity to join the Nestlé Research Center Team in investigating new frontiers for Neptune Krill Oil," said Dr. Tina Sampalis, Vice President of R&D and Business Development.

"Following the trend of tremendous growth witnessed in functional food & drink, we are extremely pleased with our collaboration with Nestlé. Moreover, in order to further capitalize on the sustainable growth of the functional food market as planned in our business plan, we are already targeting more strategic worldwide partners," said Mr. Thierry Houillon, Vice President of Business Development, Functional food at Neptune.

About Nestlé and Nestlé Research Center


Nestlé with headquarters in Vevey, Switzerland was founded in 1866 by Henri Nestlé and is today the world's biggest food and beverage company. Sales for 2006 were CHF 98.5 bn, with a net profit of CHF 9 bn.

Established in 1987, the Nestlé Research Center (NRC), Lausanne, Switzerland, is one of the world's leading research institutions in food, nutrition and life sciences. With a diverse staff of leading researchers from a broad range of scientific competencies, NRC possesses a unique blend of talent and expertise. Knowledge on nutrition and health, food science, food/consumer interaction and food quality and safety are combined at the Nestlé Research Center to help develop Good Food as a source of Good Health throughout life.

[MONSIEURCB]

Press Release Source: NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Neptune Technologies & Bioressources retains ROI Group to serve as investor relations counsel
Monday July 16, 3:50 pm ET

<< Developer of Marine-Derived Nutritional Products Seeks to Widen U.S. Investor Base >>
LAVAL, QC, July 16 /CNW Telbec/ Neptune Technologies & Bioressources Inc. (TSX.V.NTB) announced today that it has retained ROI Group LLC as its new investor relations counsel for the U.S. market. Neptune Technologies & Bioressources extracts, scientifically validates, and markets natural health products extracted from marine biomasses, and currently provides the world's only FDA-approved oil from krill.

ROI will provide NTB with a comprehensive investor outreach program to introduce its compelling investment story to a broad range of targeted potential investors, with the goal of increasing liquidity of NTB common stock and significantly enhancing NTB's shareholder value.

"We are extremely pleased to be working with ROI Group's seasoned professionals," stated Mr. André Godin, NTB Vice-President, Administration and Finance. "Our goal in hiring ROI is to help us communicate our increasingly strong investment story to target audiences both directly, and through the media," Mr. Godin continued. "Given ROI's extensive experience working with small-capitalization companies, particularly companies in the health and wellness enhancement market we are confident that ROI is well-positioned to assist us in building our U.S. shareholder base," concluded Mr. Godin.

"We are gratified to have been retained by Neptune Technologies, and confident that, based on our in depth expertise in working with companies whose products enhance health and wellness, we can dramatically increase awareness of the Company and the strong investment opportunity it represents, amongst U.S. investors," stated John Tsemberides of ROI Group.

The initial term of the agreement that includes a monthly retainer of $8,000USD is for a period of 6 months, plus an extension option for another 6 months. ROI Group LLC will also be compensated with 125,000 options in the Company exercisable at $7.50 per share for the first 6 months and 125,000 options exercisable at $8.50 per share for the second period of 6 months, if the extension option period is exercised. The options will vest over a period of 18 months and are subject to the prior acceptance of Neptune's Board of Directors.

About ROI Group LLC

ROI Group is an investor relations boutique providing a full range of investor relations services to broaden awareness and facilitate the growth of small-cap companies. ROI develops individualized strategic investor relations programs; provides access to supportive capital raising and M&A activities, and develops and implements targeted financial public relations programs. Founded in 2001, ROI serves emerging private and public companies in a broad array of industries.

[EUinside]

Exchange Codes:T-Toronto, M-Montreal, X-TSX Venture, N-New York, A-American,

Q-NASDAQ, Q2-OTCBB, I-Index   (eg.: BCE-T or BCE-N)

[EUinside]

Antwort auf Beitrag Nr.: 30.775.148 von EUinside am 20.07.07 15:40:24

Good Morning!

Einstiegsmöglichkeiten werden auch hier immer besser!

[MONSIEURCB]

Press Release Source: NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Neptune Announces Positive Results of Risk-Benefit and Health-Economics Analysis Study for NKO(TM) in the Treatment of Dyslipidemia
Thursday August 2, 12:33 pm ET

LAVAL, QC, Aug. 2 /PRNewswire-FirstCall/ - Neptune Technologies & Bioressources Inc., (TSX.V: NTB), "Neptune" is pleased to announce significantly positive results after the completion of a population-based risk-benefit and a health-economics analysis study for Neptune Krill Oil (NKO(TM)) in the management of dyslipidemia. The health-economic analysis was based on the 2003 hyperlipidemia study, a randomized, placebo controlled, clinical trial in which 90 patients who were either newly diagnosed, never treated for high cholesterol or using statins for at least 6 months, without effect, at the time of study initiation and concurrently with the study treatment.

The analysis was conducted between January and August 2007 by a team of renowned researchers: Dr. Keith Worsley MSc., PhD, FRSC and recipient of the Gold Medal, Statistical Society of Canada, affiliated with McGill University of Montreal; Dr. Shahin Jaffer, MD, FRCPC Head, Department of Medicine, Delta Hospital, University of British Columbia; and Dr. A. Shekhar Pandey, B.Sc., MD, FRCPC, ABIM, CBNC, Adult Invasive, Non-invasive, & Preventive Cardiologist, Cambridge Cardiac Care Centre, Cambridge, Ontario.

The economic model for the analysis was based on the 10-year risk for cardiovascular disease as estimated by the Framingham model. According to this model, an individual's 10-year risk for a cardiovascular event is a function of age, gender, systolic blood pressure, TC, HDL-C, smoking status and presence of left ventricular hypertrophy as detected by an electrocardiogram. The model is based on a logistic regression analysis derived on a cohort of over 5,000 patients that have been followed for 40 years or more.

The Framingham model has been shown to be a valid predictor of cardiovascular risk. Therefore, changes in the Framingham-derived risk estimates are considered to represent the change in the individual patient cardiovascular risk that are sensitive to change induced by preventive interventions. The logistic regression parameters are used to estimate the patient's 10-year risk for having a cardiovascular event.

The results of the study demonstrate the following:

a. Patients treated with NKO had significantly reduced risk for
cardiovascular events over the next 10 years, by 52%.
b. Patients treated with NKO had a significantly higher chance (-52.3%)
to prevent cardiovascular events over the next 10 years when compared
to those treated with Fish Oil (-8.9%) or the statin resistant
patients treated with low dose statin (83.6%) (P < 0.001).
c. NKO monotherapy as well as NKO co-administered with a low dose statin
was significantly more cost-effective than all other interventions
studied for all types of cardiovascular events aggregated.
d. From a cost-benefit perspective NKO remains the most favorable
treatment alternative for angina, congestive heart failure, stroke,
myocardial infarction, Percutaneous Transluminal Coronary Angioplasty
(PTCA), fatal myocardial infarction and coronary artery bypass graft
surgery (CABG); NKO has a negative cost-benefit indicating that the
cost of acquisition is less than the benefits derived from the
intervention.
e. With respect to death and cardiac arrests that are rare events, the
cost-benefit ratio is positive indicating the acquisition cost is
higher than the benefits derived. However, NKO remained the least
expensive alternative for these rare events.
f. Under the 90 day and 10 year treatment assumption, NKO maintained a
favorable cost-benefit profile with cost savings for angina, PTCA and
CABG.

The authors conclude that "The results of this analysis have shown that NKO as monotherapy or given in combination with a statin is efficient and cost-effective in the management of dyslipidemia". In addition the authors concluded that "The results have important implications for the management of the growing population of patients with dyslipidemia, who require safe and effective treatment and who may not be responsive, nor tolerant, nor appropriate candidates for treatment with a statin alone".

"Benefit, risk and economic assessments are now the pivotal points not only for government approval of medicine for treatment of diseases that require long-term care but are also considered important factors for the pharmaceutical industry decision makers before taking over the development of a new drug" stated Dr. Tina Sampalis M.D., Ph.D., Vice-President of R&D and Business Development of Neptune. "I am extremely proud that we have now successfully completed this study that was an important achievement for the pharmaceutical development of NKO. With the results of this analysis we have now provided valuable evidence that NKO reduces cardiovascular risk while remaining cost effective and even cost minimizing over many years of use."

About Neptune Technologies & Bioressources Inc.

Neptune Technologies & Bioressources Inc. develops proprietary and potent health ingredients from underexploited marine biomasses, such as krill, with its patented extraction process (Neptune OceanExtract(TM)). Using its proprietary process, Neptune Technologies & Bioressources Inc. is strategically positioning itself in the nutraceutical and pharmaceutical health and wellness market.

The Company develops and markets new formulas and new products for specific applications in high growth markets such the nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets, the next wave in nutritional research. Through strategic alliances and partnerships, as well as through clinical studies, the Company continues to demonstrate the immense beneficial effects of these products.

[EUinside]

Antwort auf Beitrag Nr.: 30.988.994 von MONSIEURCB am 02.08.07 18:36:49

4,43

+5,48 ist auch OK!

[MONSIEURCB]

Press Release Source: NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Neptune Technologies receives approval for NASDAQ listing
Thursday August 9, 1:12 pm ET

Company on Track to Achieve Goals Consistent with Business Plan
LAVAL, QC, Aug. 9 /CNW Telbec/ - Neptune Technologies & Bioressources Inc. (NASDAQ.NEPT - TSX.V.NTB) announced today that its common shares have been approved for listing on The NASDAQ Capital Market under the symbol NEPT and will begin trading on August 13, 2007. Neptune Technologies & Bioressources extracts, scientifically validates, and markets natural health products extracted from marine biomasses, and currently provides the world's only FDA-approved oil from krill, its NKO.

"We're extremely gratified to have reached this major milestone," stated Mr.André Godin, Neptune Vice-President, Administration and Finance. "As identified in our business plan and consistently communicated by management, we have intended to obtain a listing for Neptune Technologies securities on a stock exchange in the United States. Following a comprehensive evaluation of the U.S. exchanges, we determined that the NASDAQ Capital Market was the best fit for Neptune Technologies," Mr. Godin continued. "We believe this accomplishment demonstrates our commitment to meeting our goals, as set forth in our comprehensive business plan," concluded Mr. Godin.

The NASDAQ Capital Market is the largest U.S. equities exchange, with approximately 3,200 member-companies. Nasdaq-listed companies are leaders across all areas of business including technology, retail, communications, financial services, transportation, media, and biotechnology.

"Being listed on the NASDAQ Capital Market will give Neptune greater exposure and should increase liquidity for its shareholders" stated Mr. Xavier Harland, Neptune Director, Finance.

"The Listing procedure was a rigorous process, specifically the exhaustive due diligence conducted by NASDAQ. Neptune has met and will remain subject to all the NASDAQ listing requirements," added Mr. Godin.

About Neptune Technologies & Bioressources, Inc.

Neptune Technologies & Bioressources Inc. develops proprietary and potent health ingredients from underexploited marine biomasses, such as krill, with its patented extraction process (Neptune OceanExtract(TM)). Using its proprietary process, Neptune Technologies & Bioressources Inc. is strategically positioning itself in the health and wellness market.

Natural biomass extraction is now playing an important role in developing nutrigenomics, the next wave in nutritional research. Through strategic alliances and partnerships, as well as through clinical studies, the Company continues to demonstrate the immense beneficial effects of these products. The Company develops and markets new formulas and new products for specific applications in high growth markets such as the nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets.

[EUinside]

[MONSIEURCB]

Press Release Source: NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Neptune Technologies to begin trading on NASDAQ
Monday August 13, 8:30 am ET

Shares to Trade Under the Symbol NEPT
LAVAL, QC, Aug. 13 /CNW Telbec/ - Neptune Technologies & Bioressources Inc. (NASDAQ.NEPT - TSX.V.NTB) announced today that its shares will begin trading on the NASDAQ Stock Market under the symbol NEPT on Monday, August 13 at the opening bell. Neptune Technologies & Bioressources (NTB) extracts, scientifically validates, and markets natural health products extracted from marine biomasses, and currently provides the world's only FDA-approved oil from krill.

- COMPANY NAME NEPTUNE TECHNOLOGIES & BIORESSOURCES
- STOCK SYMBOL NEPT
- STOCK MARKET NASDAQ CAPITAL MARKET
- START TRADING AUGUST 13, 2007 OPENING BELL


About Neptune Technologies & Bioressources, Inc.

Neptune Technologies & Bioressources Inc. develops proprietary and potent health ingredients from underexploited marine biomasses, such as krill, with its patented extraction process (Neptune OceanExtract(TM)). Using its proprietary process, Neptune Technologies & Bioressources Inc. is strategically positioning itself in the health and wellness market.

Natural biomass extraction is now playing an important role in developing nutrigenomics, the next wave in nutritional research. Through strategic alliances and partnerships, as well as through clinical studies, the Company continues to demonstrate the immense beneficial effects of these products. The Company develops and markets new formulas and new products for specific applications in high growth markets such as the nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets.

[EUinside]

Meine Beobachtung ist beendet bin gestern eingestiegen!

Viel Erfolg an alle investierte und die es noch vorhaben. 

Der Zeitpunkt ist da. Wer zu spät kommt ...!

[EUinside]

[EUinside]

3,9

[EUinside]

Antwort auf Beitrag Nr.: 31.269.735 von EUinside am 23.08.07 15:41:29

[EUinside]

Antwort auf Beitrag Nr.: 31.330.670 von EUinside am 29.08.07 16:29:29

TSX-V: NTB
Last: 3.690
Change: +0.2100
Volume: 7500
Day High: 3.690
Day Low: 3.450
Last Trade Time: 10:09:58

Neptune Technologies & Bioressources Inc. (NTB - TSX-V) Neptune

NEPTUNE TECHNOLOGIES TO BEGIN TRADING ON NASDAQ
……………………………………
Shares to Trade Under the Symbol NEPT

Laval, Québec, CANADA – 08/13/07 – Neptune Technologies & Bioressources Inc. (NASDAQ.NEPT - TSX.V.NTB) announced today that its shares will begin trading on the NASDAQ Stock Market under the symbol NEPT on Monday, August 13 at the opening bell. Neptune Technologies & Bioressources (NTB) extracts, scientifically validates, and markets scientifically validated health ingredients extracted from marine biomasses; the Company currently provides the world’s only FDA-allowed oil from krill.

* COMPANY NAME NEPTUNE TECHNOLOGIES & BIORESSOURCES
* STOCK SYMBOL NEPT
* STOCK MARKET NASDAQ CAPITAL MARKET
* START TRADING AUGUST 13, 2007 OPENING BELL

About Neptune Technologies & Bioressources, Inc.
Neptune Technologies & Bioressources Inc. develops proprietary and potent health ingredients from underexploited marine biomasses, such as krill, with its patented extraction process (Neptune OceanExtract™). Using its proprietary process, Neptune Technologies & Bioressources Inc. is strategically positioning itself in the health and wellness market.

Natural biomass extraction is now playing an important role in developing nutrigenomics, the next wave in nutritional research. Through strategic alliances and partnerships, as well as through clinical studies, the Company continues to demonstrate the immense beneficial effects of these products. The Company develops and markets new formulas and new products for specific applications in high growth markets such as the nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets.
For further information contact:
US Contact:

ROI Group LLC
John Tsemberides
212-495-0743
[e-mail]



Canada Contact:

The Howard Group
Grant Howard
Toll free: 888-221-0915
[e-mail]
www.howardgroupinc.com
Company Contact:

Neptune Technologies & Bioressources Inc.
V.P. Administration and Finance
[e-mail]
www.neptunebiotech.com

The TSX.V has not reviewed and does not accept responsibility for the adequacy and accuracy of this news release.



Statements in this press release that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other unknown factors that could cause the actual results of the Company to be materially different from the historical results, from any future results expressed, or implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, readers are urged to consider statements labeled with the terms "believes," "belief," "expects," "intends," "anticipates," "will," or "plans" to be uncertain and forward-looking. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission.

[EUinside]

Production Plant

* Sherbrooke, Quebec
* The inaugaration of Neptune's plant was on October 9, 2002
* GMP/CFIA accredited
* Plant capacity is 60,000 kg/yr


http://www.neptunebiotech.com/video/neptunebiotech_plant_vid…

http://www.neptunebiotech.com/investorcontact.html

[EUinside]

Antwort auf Beitrag Nr.: 31.330.952 von EUinside am 29.08.07 16:48:02

[EUinside]

Antwort auf Beitrag Nr.: 31.331.036 von EUinside am 29.08.07 16:52:59

Berlin 2,53 EUR +8,58% 09:08 30.08.07

[EUinside]

[EUinside]

[EUinside]

[EUinside]

O.K. Korrektur mitgenommen mal schauen wie es weiter geht!

Bleibe jetzt an der Seitenlinie. 



...mit einen erneuten Einstieg würde ich noch warten!

[EUinside]

Antwort auf Beitrag Nr.: 31.419.761 von EUinside am 06.09.07 18:51:03

Online Handel mit kanadischen Aktien wie geht das?



Ihr könnt kanadische Aktien direkt via Internetapplikation Classic sowie über WinTrade genauso einfach handeln wie Ihr zurzeit deutsche Aktien handeln.



Ihr könnt bei der Nordnet Bank sowohl auf der Toronto Stock Exchange Börse als auch auf der TSX Venture Exchange handeln.

http://www.tsx.com/

Gruss EUinside

[MONSIEURCB]

In CA wieder deutlich über 5.-, mit massiven Umsätzen...wht's up??

[EUinside]

Antwort auf Beitrag Nr.: 31.533.701 von MONSIEURCB am 11.09.07 18:38:03

[MONSIEURCB]

Press Release Source: NEPTUNE TECHNOLOGIES & BIORESSOURCES INC.

Neptune Reports Year End Financial Results - Neptune Records 18% Sales Increase and 43% EBITDA Increase in Year End Results
Friday September 28, 4:41 pm ET

LAVAL, QC, Sept. 28 /CNW Telbec/ - Neptune Technologies & Bioressources Inc. (NASDAQ.NEPT - TSX.V.NTB), is pleased to report its financial results for the fiscal year ended May 31, 2007. During the last fiscal year, Neptune improved its productivity and operational profitability while continuing its business development strategy to penetrate the American, European and Asian markets, resulting in sustainable sales growth.

Financial Results and Highlights:

- Sales increased by 18% to $8,126,000 from $6,912,000 in the preceding
fiscal year.
- EBITDA increased by 43% to $1,504,000 from $1,049,000 in the preceding
fiscal year, representing a third consecutive year with a positive
EBITDA.
- EBITDA margin reached 18.5%, compared to 15.2% in the preceding fiscal
year.
- Excluding stock-based compensation expenses, Neptune would have
realized earnings of $152,000 instead of a loss of $2,677,000 in the
fiscal year ended May 31, 2007. Excluding stock-based compensation
expenses and an extraordinary gain from the settlement of debentures,
Neptune would have realized a loss of $1,574,000 instead of a loss of
$886,000 in the fiscal year ended May 31, 2006.


"We believe that the evaluation model and accounting method for stock-based compensation expenses are not appropriate for small capitalization fast growing companies. They do not bring the accounting value of stock-based compensation closer to the market value, as they should and as they were implemented for", stated Xavier Harland, Director of Finance.

"Neptune has managed to increase its EBITDA by $455,000 with a $1.2M increase in sales, confirming its improvement in operational efficiency", stated André Godin, Vice-President, Administration and Finance.

Neptune continues to strongly support its strategic development plan to pursue partnerships/strategic alliances with worldwide leaders in the nutraceutical and pharmaceutical industries. In accordance with its plan, Neptune has signed agreements with Nestlé and Yoplait, paving the way for its entrance into the global functional food market. Neptune is in negotiations with pharmaceutical companies with the short-term objective of penetrating the pharmaceutical market.

About Neptune Technologies & Bioressources Inc.
http://www.neptunebiotech.com